Enliven Therapeutics (ELVN) Cash from Operations Growth (1y) (2020 - 2026)
Enliven Therapeutics (ELVN) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 158.60% |
| 10 | Enliven Therapeutics | 3.31 Bn | 2.86 Bn | - | 20.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.04% |
| Dec 31, 2025 | 7.93% |
| Sep 30, 2025 | -8.91% |
| Jun 30, 2025 | 16.53% |
| Mar 31, 2025 | -3.28% |
| Dec 31, 2024 | -37.82% |
| Sep 30, 2024 | 23.29% |
| Jun 30, 2024 | -69.60% |
| Mar 31, 2024 | -12.08% |
| Dec 31, 2023 | -53.25% |
| Sep 30, 2023 | -146.53% |
| Jun 30, 2023 | -69.13% |
| Mar 31, 2023 | -101.18% |
| Dec 31, 2022 | 34.76% |
| Sep 30, 2022 | 40.86% |
| Jun 30, 2022 | 31.27% |
| Mar 31, 2022 | 20.42% |
| Dec 31, 2021 | -50.99% |
| Sep 30, 2021 | -5.36% |
| Jun 30, 2021 | -11.98% |